| Drug Name |
Solriamfetol |
| Drug ID |
BADD_D02595 |
| Description |
Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea[FDA Label]. Solriamfetol was given FDA approval in 2019[FDA Label]. |
| Indications and Usage |
Solriamfetol is indicated for treatment of daytime sleepiness associated with obstructive sleep apnea and narcolepsy, but is not a treatment for the underlying airway obstruction in apnea patients[FDA Label][A176534,A176744]. |
| Marketing Status |
approved |
| ATC Code |
N06BA14 |
| DrugBank ID |
DB14754
|
| KEGG ID |
D11315
|
| MeSH ID |
C000623308
|
| PubChem ID |
10130337
|
| TTD Drug ID |
D0M3CV
|
| NDC Product Code |
44639-002; 68727-351; 68727-350; 81968-350; 81968-351; 44639-003; 44639-004 |
| UNII |
939U7C91AI
|
| Synonyms |
solriamfetol | (2R)-2-amino-3-phenylpropyl carbamate | benzenepropanol, beta-amino-, carbamate (ester), (betaR)- | ADX-N05 | Sunosi | (R)-2-amino-3-phenylpropylcarbamate hydrochloride | JZP-110 | solriamfetol hydrochloride |
